spacer
home > epc > autumn 2003 > make or buy? a strategic assessment of the benefits of outsourcing
PUBLICATIONS
European Pharmaceutical Contractor

Make or Buy? A Strategic Assessment of the Benefits of Outsourcing

Outsourcing has many converts across the manufacturing sector. But rather than join the evangelical throng urging companies to shed assets and be born again as product designers, solutions providers, industry innovators or supply chain integrators, this article advises manufacturers to take more of an agnostic approach and not to regard outsourcing as a panacea for every ill.

On the surface, the arguments for outsourcing are compelling. Improved information technology and communication links, falling interaction costs and global access to vendors mean that manufacturers now can choose more freely than ever before how to structure their business. In one stroke, outsourcing seems to offer the chance to dump operational headaches and bottlenecks, sidestep labour conflicts and management deficiencies and secure immediate cost savings.

But, while it is undoubtedly true that outsourcing lightens a company's asset base, if manufacturers automatically assume that it is the solution they will be failing to address the core question - that of how to improve a company's performance and maximise value.

Statistics indicate that growing numbers of businesses are becoming disenchanted with outsourcing. Dun & Bradstreet report that 20 to 25 per cent of all outsourcing relationships fail within two years and 50 per cent fail within five, the costs of which are high. Possible ramifications for a company include one-time and year-on-year financial goals being missed, delays in outsourcing timelines, lowered workforce morale and productivity, dissatisfied customers, greater consumption of management resources and large switching costs should operations need to be brought back in-house.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Blair McCallum, Head of McKinsey & Company's Production System Design Centre (PSDC)

Blair McCallum is the Head of McKinsey & Company's Production System Design Centre (PSDC). He has worked at Toyota, where he was part of the team that developed the European supplier base, and was responsible for Toyota production system training throughout Europe.

In 1995, he moved to Rover Group as a Senior Manager and subsequently became General Manager responsible for the supplier base and its five main manufacturing plants. Since joining PSDC in August 1998, Blair has worked with UK manufacturing companies of varying sizes and across all sectors to help transform their production processes.

spacer
Blair McCallum
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement